Fresh analysis indicates that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Published data in a major health publication shows that while overweight people often shed about a fifth of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People purchasing these medications should be aware of the danger of rapid weight regain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to original weight within about 18 months.
Analyzing Therapies
The analysis, which examined 37 of trials involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.
The team note that individuals who lose weight through diet and exercise usually have a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Regain
Nutrition scientists propose the mechanism of the drugs accounts for the amplified weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is unsuppressed, making binge eating far more likely."
A Chronic Disease?
The NHS suggest the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
Many experts contend that, due to the significant potential of weight regain, the therapy might need to be long-term.
This view is reinforced by drug manufacturers, who note that the results "highlight the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
People who have discontinued the medication describe a powerful return of appetite.
"It was like a trigger flipping and I was suddenly starving," recalled a patient.
This difficulty is worsened if patients have not established lasting dietary or behavioural changes during treatment.
Widespread Adoption
Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and long-term success likely depends on combined behavioural changes.
